Development of non-GAT1-selective inhibitors: Challenges and achievements

Advances in Neurobiology

Volumn 16, Issue , 2017, Pages 315-332

  Damgaard, Maria ^a   Haugaard, Anne Stæhr ^a   Kickinger, Stefanie ^b   Al Khawaja, Anas ^a   Lie, Maria E K ^a   Ecker, Gerhard F ^b   Clausen, Rasmus Prætorius ^a   Frølund, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

BGT1; GABA transporters; GAT; GAT1; GAT3; Non GAT1 selective inhibitors

Indexed keywords

4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; AROMATIC AMINO ACID; BETA ALANINE; BETAINE; GABA TRANSPORTER 1; GUVACINE; ISOSERINE; NIPECOTIC ACID; TIAGABINE; 4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID UPTAKE INHIBITOR;

CHEMICAL STRUCTURE; DRUG RESEARCH; DRUG SELECTIVITY; HUMAN; ION TRANSPORT; LIPOPHILICITY; MEDICINAL CHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEOMICS; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN; METABOLISM;

ANIMALS; BRAIN; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GABA UPTAKE INHIBITORS; HUMANS;

EID: 85028073691     PISSN: 21905215     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-55769-4_16     Document Type: Chapter

References (65)

1. Al-Khawaja A, Petersen JG, Damgaard M, Jensen MH, Vogensen SB, Lie ME, et al. Pharmacological identification of a guanidine-containing β-alanine analogue with low micromolar potency and selectivity for the betaine/GABA transporter 1 (BGT1). Neurochem Res. 2014;39(10):1988–96.
2. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The concise guide to pharmacology 2015/16: transporters. Br J Pharmacol. 2015;172(24):6110–202.
3. Ali FE, Bondinell WE, Dandridge PA, Frazee JS, Garvey E, Girard GR, et al. Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985;28(5):653–60.
4. Baglo Y, Gabrielsen M, Sylte I, Gederaas OA. Homology modeling of human gamma-butyric acid transporters and the binding of pro-drugs 5-aminolevulinic acid and methyl aminolevulinic acid used in photodynamic therapy. PLoS One. 2013;8(6):e65200.
5. Beuming T, Shi L, Javitch JA, Weinstein H. A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol. 2006;70(5):1630–42.
6. Bock E, Hamberger A. Immunoelectrophoretic determination of brain-specific antigens in bulk-prepared neuronal and glial cells. Brain Res. 1976;112(2):329–35.
7. Bolvig T, Larsson OM, Pickering DS, Nelson N, Falch E, Krogsgaard-Larsen P, et al. Action of bicyclic isoxazole GABA analogues on GABA transporters and its relation to anticonvulsant activity. Eur J Pharmacol. 1999;375(1–3):367–74.
8. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int. 1996;29(4):335–56.
9. Borden LA, Smith KE, Hartig PR, Branchek TA, Weinshank RL. Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system. Cloning of two novel high affinity GABA transporters from rat brain. J Biol Chem. 1992;267(29):21098–104.
10. Borden LA, Smith KE, Gustafson EL, Branchek TA, Weinshank RL. Cloning and expression of a betaine/Gaba transporter from human brain. J Neurochem. 1995;64(3):977–84.
11. Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJ, Andersen KE, Jansen JA, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem. 1990;54(2):639–47.
12. Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol. 2002;136(7):965–74.
13. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature. 2010;468(7321):305–9.
14. Clausen RP, Moltzen EK, Perregaard J, Lenz SM, Sanchez C, Falch E, et al. Selective inhibitors of GABA uptake: synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol analogues. Bioorg Med Chem. 2005;13(3):895–908.
15. Clausen RP, Madsen K, Larsson OM, Frolund B, Krogsgaard-Larsen P, Schousboe A. Structure-activity relationship and pharmacology of gamma-aminobutyric acid (GABA) transport inhibitors. Adv Pharmacol. 2006;54:265–84.
16. Coleman JA, Green EM, Gouaux E. X-ray structures and mechanism of the human serotonin transporter. Nature. 2016;532(7599):334–9.
17. Conti F, Melone M, De Biasi S, Minelli A, Brecha NC, Ducati A. Neuronal and glial localization of GAT-1, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex. J Comp Neurol. 1998;396(1):51–63.
18. Conti F, Zuccarello LV, Barbaresi P, Minelli A, Brecha NC, Melone M. Neuronal, glial, and epithelial localization of gamma-aminobutyric acid transporter 2, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures. J Comp Neurol. 1999;409(3):482–94.
19. Conti F, Minelli A, Melone M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res Rev. 2004;45(3):196–212.
20. Damgaard M, Al-Khawaja A, Vogensen SB, Jurik A, Sijm M, Lie MEK, et al. Identification of the first highly subtype-selective inhibitor of human GABA transporter GAT3. ACS Chem Neurosci. 2015;6(9):1591–9.
21. Dhar TGM, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, et al. Design, synthesis and evaluation of substituted triarylnipecotic acid-derivatives as Gaba uptake inhibitors – identification of a ligand with moderate affinity and selectivity for the cloned human Gaba transporter Gat-3. J Med Chem. 1994;37(15):2334–42.
22. Falch E, Perregaard J, FrLlund B, Søkilde B, Buur A, Hansen LM, et al. Selective inhibitors of glial GABA uptake: synthesis, absolute stereochemistry, and pharmacology of the enantio-mers of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole (exo-THPO) and analogues. J Med Chem. 1999;42(26):5402–14.
23. Fjalland B. Inhibition by neuroleptics of uptake of 3H-GABA into rat brain synaptosomes. Acta Pharmacol Toxicol (Copenh). 1978;42(1):73–6.
24. Fülep GH, Hoesl CE, Hofner G, Wanner KT. New highly potent GABA uptake inhibitors selective for GAT-1 and GAT-3 derived from (R)- and (S)-proline and homologous pyrrolidine-2-alkanoic acids. Eur J Med Chem. 2006;41(7):809–24.
25. Hertz E, Yu ACH, Hertz L, Juurlink BHJ, Schousboe A. Preparation of primary cultures of mouse cortical neurons. In: Shahar A, de Vellis J, Vernadakis A, Haber B, editors. A dissection and tissue culture manual of the nervous system, vol. 40. New York: Alan R. Liss, Inc.; 1989a. p. 183–6.
26. Hertz L, Juurlink BHJ, Hertz E, Fosmark H, Schousboe A. Preparation of primary cultures of mouse (rat) astrocyte. In: Shahar A, de Vellis J, Vernadakis A, Haber B, editors. A dissection and tissue culture manual of the nervous system, vol. 21. New York: Alan R. Liss, Inc.; 1989b. p. 105–8.
27. Jurik A, Zdrazil B, Holy M, Stockner T, Sitte HH, Ecker GF. A binding mode hypothesis of tiagabine confirms liothyronine effect on gamma-aminobutyric acid transporter 1 (GAT1). J Med Chem. 2015;58(5):2149–58.
28. Kalviainen R. Long-term safety of tiagabine. Epilepsia. 2001;42(Suppl 3):46–8.
29. Kanner BI. Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes. J Biol Chem. 2003;278(6):3705–12.
30. Kobayashi T, Suemasa A, Igawa A, Ide S, Fukuda H, Abe H, et al. Conformationally restricted GABA with bicyclo[3.1.0]hexane backbone as the first highly selective BGT-1 inhibitor. ACS Med Chem Lett. 2014;5(8):889–93.
31. Kragholm B, Kvist T, Madsen KK, Jorgensen L, Vogensen SB, Schousboe A, et al. Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a noncompetitive pharmacological profile. Biochem Pharmacol. 2013;86(4):521–8.
32. Kragler A, Hofner G, Wanner KT. Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. Eur J Pharmacol. 2005;519(1–2):43–7.
33. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011;63(3):585–640.
34. Krogsgaard-Larsen P. Inhibitors of the GABA uptake systems. Mol Cell Biochem. 1980;31(2):105–21.
35. Krogsgaard-Larsen P, Johnston GA. Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds. J Neurochem. 1975;25(6):797–802.
36. Krogsgaard-Larsen P, Brehm L, Schaumburg K. Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure. Acta Chem Scand B. 1981;35(5):311–24.
37. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res. 1987;1(2):77–93.
38. Kvist T, Christiansen B, Jensen AA, Brauner-Osborne H. The four human gamma-aminobutyric acid (GABA) transporters: pharmacological characterization and validation of a highly efficient screening assay. Comb Chem High Throughput Screen. 2009;12(3):241–9.
39. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90(1):21–34.
40. Lie MEK, Al-Khawaja A, Damgaard M, Haugaard AS, Schousboe A, Clarkson AN, Wellendorph P. Glial GABA transporters as modulators of inhibitory signalling in epilepsy and stroke. Adv Neurobiol. 2017; 16, in press.
41. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. J Biol Chem. 1993;268(3):2106–12.
42. Madsen KK, White HS, Schousboe A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther. 2010;125(3):394–401.
43. Melone M, Barbaresi P, Fattorini G, Conti F. Neuronal localization of the GABA transporter GAT-3 in human cerebral cortex: a procedural artifact? J Chem Neuroanat. 2005;30(1):45–54.
44. Nakada K, Yoshikawa M, Ide S, Suemasa A, Kawamura S, Kobayashi T, et al. Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports. Bioorg Med Chem. 2013;21(17):4938–50.
45. Pabel J, Faust M, Prehn C, Wörlein B, Allmendinger L, Höfner G, et al. Development of an (S)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] carba analogue inhibitor for murine γ-aminobutyric acid transporter type 4. ChemMedChem. 2012;7(7):1245–55.
46. Penmatsa A, Wang KH, Gouaux E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature. 2013;503(7474):85–90.
47. Petersen JG, Sorensen T, Damgaard M, Nielsen B, Jensen AA, Balle T, et al. Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists. Eur J Med Chem. 2014;84:404–16.
48. Petrera M, Wein T, Allmendinger L, Sindelar M, Pabel J, Hofner G, et al. Development of highly potent GAT1 inhibitors: synthesis of nipecotic acid derivatives by Suzuki-Miyaura cross-coupling reactions. ChemMedChem. 2016;11(5):519–38.
49. Schaffert ES, Hofner G, Wanner KT. Aminomethyltetrazoles as potential inhibitors of the gamma-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation. Bioorg Med Chem. 2011;19(21):6492–504.
50. Schlessinger A, Wittwer MB, Dahlin A, Khuri N, Bonomi M, Fan H, et al. High selectivity of the gamma-aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach. J Biol Chem. 2012;287(45):37745–56.
51. Schmitt S, Hofner G, Wanner KT. Application of MS transport assays to the four human gamma-aminobutyric acid transporters. ChemMedChem. 2015;10(9):1498–510.
52. Schousboe A, Thorbek P, Hertz L, Krogsgaard-Larsen P. Effects of GABA analogues of restricted conformation on GABA transport in astrocytes and brain cortex slices and on GABA receptor binding. J Neurochem. 1979;33(1):181–9.
53. Schousboe A, Larsson OM, Hertz L, Krogsgaard-Larsen P. Heterocyclic GABA analogues as selective inhibitors of astroglial GABA uptake. Adv Biochem Psychopharmacol. 1981;29:135–41.
54. Schousboe A, Larsson OM, Wood JD, Krogsgaard-Larsen P. Transport and metabolism of gamma- aminobutyric acid in neurons and glia: implications for epilepsy. Epilepsia. 1983;24(5):531–8.
55. Schousboe A, Wellendorph P, Frølund B, Clausen RP, Krogsgaard-Larsen P. Astrocytic GABA-transporters: pharmacological properties and targets for antiepileptic drugs. Adv Nerobiol. 2017; 16, in press.
56. Skovstrup S, Taboureau O, Brauner-Osborne H, Jorgensen FS. Homology modelling of the GABA transporter and analysis of tiagabine binding. ChemMedChem. 2010;5(7):986–1000.
57. Thomsen C, Sorensen PO, Egebjerg J. 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol. 1997;120(6):983–5.
58. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(Suppl 3):8–12.
59. Vogensen SB, Jorgensen L, Madsen KK, Borkar N, Wellendorph P, Skovgaard-Petersen J, et al. Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization. J Med Chem. 2013;56(5):2160–4.
60. Vogensen SB, Jorgensen L, Madsen KK, Jurik A, Borkar N, Rosatelli E, et al. Structure activity relationship of selective GABA uptake inhibitors. Bioorg Med Chem. 2015;23(10):2480–8.
61. Wein T, Wanner KT. Generation of a 3D model for human GABA transporter hGAT-1 using molecular modeling and investigation of the binding of GABA. J Mol Model. 2010;16(1):155–61.
62. Wein T, Petrera M, Allmendinger L, Hofner G, Pabel J, Wanner KT. Different binding modes of small and large binders of GAT1. ChemMedChem. 2016;11(5):509–18.
63. White HS, Sarup A, Bolvig T, Kristensen AS, Petersen G, Nelson N, et al. Correlation between anticonvulsant activity and inhibitory action on glial gamma-aminobutyric acid uptake of the highly selective mouse gamma-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated analogs. J Pharmacol Exp Ther. 2002;302(2):636–44.
64. White HS, Watson WP, Hansen SL, Slough S, Perregaard J, Sarup A, et al. First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther. 2005;312(2):866–74.
65. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature. 2005;437(7056):215–23.